Wenyan Wang

Wenyan Wang

Auto-generated profile, based on publicly available information

Wenyan Wang

School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
WWWenyan Wang
Wenyan Wang
SYShun-Yu Yao
Shun-Yu Yao
JLJingjing Luo
Jingjing Luo
CDChendi Ding
Chendi Ding
QHQili Huang
Qili Huang
Hongzhong ChenHongzhong Chen
Hongzhong Chen
Hypoxic tumors present a significant challenge in cancer therapy due to their ability to adaptation in low-oxygen environments, which supports tumor survival and resistance to treatment. Enhanced mitophagy, the selective degradation of mitochondria by autophagy, is a crucial mechanism that helps sustain cellular homeostasis in hypoxic tumors. In this study, we develop an azocalix[4]arene-modified supramolecular albumin nanoparticle, that co-delivers hydroxychloroquine and a mitochondria-targeting photosensitizer, designed to induce cascaded oxidative stress by regulating mitophagy for the treatment of hypoxic tumors. These nanoparticles are hypoxia-responsive and release loaded guest molecules in hypoxic tumor cells. The released hydroxychloroquine disrupts the mitophagy process, thereby increasing oxidative stress and further weakening the tumor cells. Additionally, upon laser irradiation, the photosensitizer generates reactive oxygen species independent of oxygen, inducing mitochondria damage and mitophagy activation. The dual action of simultaneous spatiotemporal mitophagy activation and mitophagy flux blockade results in enhanced autophagic and oxidative stress, ultimately driving tumor cell death. Our work highlights the effectiveness of hydroxychloroquine-mediated mitophagy blockade combined with mitochondria-targeted photosensitizer for cascade-amplified oxidative stress against hypoxic tumors.

27 September 2024 in Science Advances
Verified
Journal Article
Open access
QHQili Huang
Qili Huang
CDChendi Ding
Chendi Ding
WWWenyan Wang
Wenyan Wang
LYLi Yang
Li Yang
YWYinglong Wu
Yinglong Wu
Hongzhong ChenHongzhong Chen
Hongzhong Chen
Despite targeted therapies like epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), non–small cell lung cancer (NSCLC) remains a clinical challenge due to drug resistance hampering their efficacy. Here, we designed an “AND” logic gate–based supramolecular therapeutic platform (HA-BPY-GEF-NPs) for the treatment of EGFR-TKI resistant NSCLC. This system integrates both internal and external stimuli–responsive mechanisms that need to be activated in a preset sequence, enabling it to precisely control drug release behavior for enhancing therapeutic precision. By programming the system to respond to sequential near-infrared (NIR) irradiation and enzyme (cathepsin B) inputs, the release of gefitinib is effectively confined to the tumor region. Moreover, the NIR irradiation induces reactive oxygen species production, suppressing tumor growth and inhibiting bypass signaling pathways. The designed drug delivery system offers a highly controlled and targeted therapeutic approach, effectively inhibiting tumor growth, suppressing bypass signaling pathways, and overcoming EGFR-TKI resistance, thus offering a potential solution for maximizing therapeutic benefits.

19 February 2024 in Advanced Functional Materials
Verified
Journal Article
Closed access
WWWenyan Wang
Wenyan Wang
PTPhoebe Huijun Tham
Phoebe Huijun Tham
CDChendi Ding
Chendi Ding
PHPing Huang
Ping Huang
TLTingxuan Li
Tingxuan Li
YZYanli Zhao
Yanli Zhao

28 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
WWWenyan Wang
Wenyan Wang
SYShun-Yu Yao
Shun-Yu Yao
JLJingjing Luo
Jingjing Luo
CDChendi Ding
Chendi Ding
QHQili Huang
Qili Huang
Hongzhong ChenHongzhong Chen
Hongzhong Chen